**Discounts available for COVID-19-related research. Click 'Request More Info' button on this page to ask about offer details.**
Olink Proteomics is a Swedish company dedicated to innovation, quality, rigor and transparency, providing outstanding products and services for human protein biomarker discovery. Our groundbreaking high-multiplex biomarker panels for precision proteomics help scientists make research decisions more quickly and confidently through robust, targeted biomarker discovery. Our high quality multiplex immunoassay panels help bring new insights into disease processes, improve disease detection, and contribute to a better understanding of biology. Based on the pioneering research of Professor Ulf Landegren and his group at Uppsala University, Sweden, Olink was founded in 2004, The company has a successful history of developing molecular technologies, with a broad IP portfolio. Many of these have been commercialized through out-licensing to industry leading partners such as Affymetrix, Life Technologies, and through the spin-out companies Qlinea and Halo Genomics (now part of Agilent). Olink sold its highly successful Duolink product line for in situ detection of proteins to Sigma-Aldrich in 2015 and is now focused fully on its high-multiplex immunoassay panels for protein biomarker discovery. The company has gone through a significant expansion since mid-2015 and established a strong US regional organization during 2016, based in Boston, MA.
Olink: Precision Proteomics, to enable Precision Medicine
Our protein biomarker panels enable rapid, robust identification of protein signatures to:
Just 1 µL of almost any type of human biological sample is sufficient to measure 92 proteins simultaneously, and each kit can process up to 96 samples in less than 24 hours. Customers can choose to run the kits in their own lab, or send their samples for analysis at Olink's Anaysis Service laboratory in Boston, MA.
The current Olink offering includes almost 1000 human protein assays, available via twelve 92-plex panels, each focused on a specific disease (2 CVD panels, Inflammation, Oncology, Neurology & Immuno-oncology) or biological process (Cardiometabolism, Cell Regulation, Development, Immune Response, Metabolism & Organ Damage). This provides a proteomics-scale tool with which to cast a broad net for biomarker discovery, while providing the flexibility of focused panels to meet different customer needs. (Visit www.olink.com/products for more details).
Olink's panels are based on our proprietary Proximity Extension Assay (PEA) technology, which uses pairs of matched antibodies linked to complementary oligonucleotide strands for each protein target. This dual-recognition, DNA-coupled methodology with qPCR readout provides exceptional specificity and overcomes the problems normally associated with multiplexed immunoassays. (Learn more at www.olink.com/PEA).
All Olink assays are thoroughly validated, and this data is made freely accessible on the Olink website. Additional biostatistical support services are also available on request.
Olink Proteomics AB has not received any endorsements.